Evogene Historical Income Statement

EVGN Stock

USD 1.62 0.02 1.25%

Historical analysis of Evogene income statement accounts such as Selling General Administrative of 5.2 M or Total Revenue of 6 M can show how well Evogene performed in making a profits. Evaluating Evogene income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Evogene's future profits or losses.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Evogene latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Evogene is a good buy for the upcoming year.

Net Income Gross Profit

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evogene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

To learn how to invest in Evogene Stock, please use our How to Invest in Evogene guide.

About Evogene Income Statement Analysis

Evogene Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Evogene shareholders. The income statement also shows Evogene investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Evogene Income Statement Chart

At this time, Evogene's Net Interest Income is very stable compared to the past year. As of the 23rd of November 2024, Reconciled Depreciation is likely to grow to about 2.7 M, while Interest Expense is likely to drop about 162.4 K.

Interest Expense Selling General Administrative Total Revenue Gross Profit Other Operating Expenses Ebit

Interest Expense

The cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit.

Total Revenue

Total revenue comprises all receipts Evogene generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Gross Profit

Gross profit is a required income statement account that reflects total revenue of Evogene minus its cost of goods sold. It is profit before Evogene operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Evogene. It is also known as Evogene overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Most accounts from Evogene's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Evogene current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evogene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

To learn how to invest in Evogene Stock, please use our How to Invest in Evogene guide.At this time, Evogene's Net Interest Income is very stable compared to the past year. As of the 23rd of November 2024, Reconciled Depreciation is likely to grow to about 2.7 M, while Interest Expense is likely to drop about 162.4 K.

	2021	2022	2023	2024 (projected)
Interest Expense	1.4M	3.3M	171K	162.5K
Depreciation And Amortization	2.2M	2.6M	2.6M	2.8M

Interest Expense Depreciation And Amortization

Evogene income statement Correlations

	Depreciation And Amortization	Interest Expense	Selling General Administrative	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Net Income From Continuing Ops	Interest Income	Minority Interest	Tax Provision	Net Interest Income	Reconciled Depreciation	Selling And Marketing Expenses
Depreciation And Amortization		0.15	0.06	-0.63	-0.59	0.08	-0.48	-0.46	0.47	-0.37	-0.62	0.4	-0.47	-0.09	-0.5	0.52	-0.39	-0.29	0.67	-0.12	-0.31	0.58	0.06
Interest Expense	0.15		0.19	-0.44	-0.45	0.35	-0.44	-0.48	0.56	-0.49	-0.42	0.5	-0.53	-0.55	-0.52	0.3	-0.56	0.01	0.25	0.54	-0.77	0.11	0.43
Selling General Administrative	0.06	0.19		-0.47	-0.48	0.73	-0.7	-0.72	0.61	-0.75	-0.45	0.77	-0.7	-0.08	-0.65	0.4	-0.7	-0.27	0.23	-0.04	-0.27	0.5	0.44
Total Revenue	-0.63	-0.44	-0.47		0.97	-0.35	0.86	0.87	-0.83	0.84	0.98	-0.8	0.85	0.16	0.85	-0.69	0.9	-0.1	-0.59	0.1	0.58	-0.54	-0.31
Gross Profit	-0.59	-0.45	-0.48	0.97		-0.48	0.91	0.9	-0.89	0.87	0.89	-0.85	0.89	0.31	0.9	-0.69	0.89	-0.19	-0.47	0.14	0.46	-0.45	-0.25
Other Operating Expenses	0.08	0.35	0.73	-0.35	-0.48		-0.75	-0.72	0.77	-0.74	-0.22	0.83	-0.76	-0.58	-0.76	0.45	-0.64	0.03	0.05	-0.08	-0.09	0.26	0.3
Operating Income	-0.48	-0.44	-0.7	0.86	0.91	-0.75		0.99	-0.97	0.98	0.79	-0.97	0.99	0.39	0.99	-0.72	0.95	-0.07	-0.44	0.14	0.41	-0.55	-0.39
Ebit	-0.46	-0.48	-0.72	0.87	0.9	-0.72	0.99		-0.94	1.0	0.81	-0.96	0.98	0.31	0.97	-0.65	0.97	0.0	-0.48	0.04	0.49	-0.59	-0.47
Research Development	0.47	0.56	0.61	-0.83	-0.89	0.77	-0.97	-0.94		-0.93	-0.75	0.97	-0.97	-0.51	-0.98	0.71	-0.92	0.16	0.42	-0.09	-0.47	0.44	0.32
Ebitda	-0.37	-0.49	-0.75	0.84	0.87	-0.74	0.98	1.0	-0.93		0.78	-0.96	0.97	0.31	0.96	-0.63	0.97	-0.04	-0.42	0.03	0.48	-0.56	-0.49
Cost Of Revenue	-0.62	-0.42	-0.45	0.98	0.89	-0.22	0.79	0.81	-0.75	0.78		-0.73	0.78	0.04	0.77	-0.66	0.86	-0.02	-0.65	0.06	0.65	-0.58	-0.34
Total Operating Expenses	0.4	0.5	0.77	-0.8	-0.85	0.83	-0.97	-0.96	0.97	-0.96	-0.73		-0.97	-0.44	-0.97	0.69	-0.94	0.04	0.4	-0.08	-0.45	0.5	0.39
Income Before Tax	-0.47	-0.53	-0.7	0.85	0.89	-0.76	0.99	0.98	-0.97	0.97	0.78	-0.97		0.46	1.0	-0.75	0.96	-0.03	-0.43	0.06	0.46	-0.54	-0.44
Total Other Income Expense Net	-0.09	-0.55	-0.08	0.16	0.31	-0.58	0.39	0.31	-0.51	0.31	0.04	-0.44	0.46		0.49	-0.51	0.3	-0.32	0.04	0.07	0.04	0.1	0.08
Net Income	-0.5	-0.52	-0.65	0.85	0.9	-0.76	0.99	0.97	-0.98	0.96	0.77	-0.97	1.0	0.49		-0.76	0.94	-0.06	-0.41	0.09	0.43	-0.51	-0.4
Income Tax Expense	0.52	0.3	0.4	-0.69	-0.69	0.45	-0.72	-0.65	0.71	-0.63	-0.66	0.69	-0.75	-0.51	-0.76		-0.69	0.12	0.39	-0.12	-0.35	0.43	0.26
Net Income From Continuing Ops	-0.39	-0.56	-0.7	0.9	0.89	-0.64	0.95	0.97	-0.92	0.97	0.86	-0.94	0.96	0.3	0.94	-0.69		-0.06	-0.46	-0.03	0.6	-0.53	-0.5
Interest Income	-0.29	0.01	-0.27	-0.1	-0.19	0.03	-0.07	0.0	0.16	-0.04	-0.02	0.04	-0.03	-0.32	-0.06	0.12	-0.06		-0.22	-0.4	0.2	-0.48	-0.5
Minority Interest	0.67	0.25	0.23	-0.59	-0.47	0.05	-0.44	-0.48	0.42	-0.42	-0.65	0.4	-0.43	0.04	-0.41	0.39	-0.46	-0.22		-0.05	-0.58	0.85	0.1
Tax Provision	-0.12	0.54	-0.04	0.1	0.14	-0.08	0.14	0.04	-0.09	0.03	0.06	-0.08	0.06	0.07	0.09	-0.12	-0.03	-0.4	-0.05		-0.61	0.03	0.71
Net Interest Income	-0.31	-0.77	-0.27	0.58	0.46	-0.09	0.41	0.49	-0.47	0.48	0.65	-0.45	0.46	0.04	0.43	-0.35	0.6	0.2	-0.58	-0.61		-0.46	-0.59
Reconciled Depreciation	0.58	0.11	0.5	-0.54	-0.45	0.26	-0.55	-0.59	0.44	-0.56	-0.58	0.5	-0.54	0.1	-0.51	0.43	-0.53	-0.48	0.85	0.03	-0.46		0.43
Selling And Marketing Expenses	0.06	0.43	0.44	-0.31	-0.25	0.3	-0.39	-0.47	0.32	-0.49	-0.34	0.39	-0.44	0.08	-0.4	0.26	-0.5	-0.5	0.1	0.71	-0.59	0.43

Click cells to compare fundamentals

Evogene Account Relationship Matchups

Evogene income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	5.2M	2.7M	2.2M	2.6M	2.6M	2.8M
Interest Expense	386K	3.0M	1.4M	3.3M	171K	162.5K
Selling General Administrative	3.8M	5.3M	7.3M	6.5M	8.7M	5.2M
Total Revenue	753K	1.0M	930K	1.7M	5.6M	6.0M
Gross Profit	419K	466K	163K	766K	1.4M	2.1M
Other Operating Expenses	21.9M	25.9M	31.9M	28.6M	32.0M	28.6M
Operating Income	(21.2M)	(24.8M)	(31.0M)	(26.9M)	(26.4M)	(27.7M)
Ebit	(21.2M)	(25.9M)	(30.0M)	(29.5M)	(25.8M)	(27.1M)
Research Development	17.8M	20.0M	23.9M	20.8M	18.1M	18.0M
Ebitda	(15.9M)	(23.2M)	(27.8M)	(26.9M)	(23.2M)	(24.4M)
Cost Of Revenue	334K	574K	767K	909K	4.2M	3.9M
Total Operating Expenses	21.6M	25.3M	31.1M	27.7M	27.8M	23.3M
Income Before Tax	(19.1M)	(26.2M)	(30.4M)	(29.8M)	(26.0M)	(27.3M)
Total Other Income Expense Net	2.1M	(1.4M)	521K	687K	404K	424.2K
Net Income Applicable To Common Shares	(18.1M)	(23.4M)	(27.8M)	(26.6M)	(24.0M)	(25.2M)
Net Income	(19.1M)	(23.4M)	(27.8M)	(26.6M)	(23.9M)	(25.1M)
Income Tax Expense	24K	32K	13K	90K	(33K)	(34.7K)
Net Income From Continuing Ops	(19.1M)	(26.2M)	(30.4M)	(29.8M)	(22.4M)	(23.6M)
Interest Income	759K	1.6M	1.9M	516K	631K	1.1M
Minority Interest	10.1M	10.8M	2.7M	3.2M	2.2M	3.7M
Tax Provision	24K	32K	13K	90K	16K	15.2K
Net Interest Income	405K	(1.4M)	521K	(2.8M)	2.8M	3.0M
Reconciled Depreciation	2.8M	2.7M	2.2M	2.6M	2.6M	2.7M

Pair Trading with Evogene

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Evogene position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Evogene will appreciate offsetting losses from the drop in the long position's value.

Moving together with Evogene Stock

0.79	ME	23Andme Holding	Pair Corr
0.9	VALN	Valneva SE ADR	Pair Corr
0.68	JNJ	Johnson Johnson Sell-off Trend	Pair Corr

Moving against Evogene Stock

0.54	MDGL	Madrigal Pharmaceuticals	Pair Corr
0.43	MLYS	Mineralys Therapeutics,	Pair Corr
0.41	KZR	Kezar Life Sciences	Pair Corr
0.41	RNXT	RenovoRx	Pair Corr
0.4	NXGLW	NexGel Warrant	Pair Corr

The ability to find closely correlated positions to Evogene could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Evogene when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Evogene - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Evogene to buy it.

The correlation of Evogene is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Evogene moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Evogene moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Evogene can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Evogene offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Evogene's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Evogene Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Evogene Stock:

How To Invest In Evogene

Details

Is Evogene Stock a good investment?

Details

What is Evogene's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

To learn how to invest in Evogene Stock, please use our How to Invest in Evogene guide.

You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evogene. If investors know Evogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evogene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(3.84)

Revenue Per Share

1.881

Quarterly Revenue Growth

0.398

Return On Assets

(0.28)

Return On Equity

(0.82)

The market value of Evogene is measured differently than its book value, which is the value of Evogene that is recorded on the company's balance sheet. Investors also form their own opinion of Evogene's value that differs from its market value or its book value, called intrinsic value, which is Evogene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evogene's market value can be influenced by many factors that don't directly affect Evogene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Evogene's value and its price as these two are different measures arrived at by different means. Investors typically determine if Evogene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evogene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Evogene Historical Income Statement

About Evogene Income Statement Analysis

Evogene Income Statement Chart

Interest Expense

Total Revenue

Gross Profit

Other Operating Expenses

Evogene income statement Correlations

Evogene Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Evogene income statement Accounts

Pair Trading with Evogene

Moving together with Evogene Stock

Moving against Evogene Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Ebitda	+ 1.0	Ebit
Net Income	+ 1.0	Income Before Tax
Ebit	+ 0.99	Operating Income
Income Before Tax	+ 0.99	Operating Income
Net Income	+ 0.99	Operating Income
Cost Of Revenue	+ 0.98	Total Revenue

Net Income	- 0.98	Research Development
Net Income	- 0.97	Total Operating Expenses
Income Before Tax	- 0.97	Total Operating Expenses
Income Before Tax	- 0.97	Research Development
Total Operating Expenses	- 0.97	Operating Income
Research Development	- 0.97	Operating Income